Fondaparinux (Arixtra)

Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.

Also Known As:

Arixtra; Fondaparinux Sodium; Quixidar; (2S,3S,4R,5R,6R)-6-((2R,3R,4R,5R,6R)-6-((2R,3S,4S,5R,6R)-2-carboxy-4-hydroxy-6-((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-(sulfooxymethyl)oxan-3-yl)oxy-5-sulfooxyoxan-3-yl)oxy-5-(sulfoamino)-4-sulfooxy-2-(sulfooxymethyl)oxan-3-yl)oxy-3-((2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfoamino)-6-(sulfooxymethyl)oxan-2-yl)oxy-4,5-dihydroxyoxane-2-carboxylic acid

Networked: 928 relevant articles (101 outcomes, 216 trials/studies)

Relationship Network

Drug Context: Research Results

Carbohydrates: 22023
- Polysaccharides: 15383
  - Oligosaccharides: 3566
    - Fondaparinux: 928

Experts

1.	Warkentin, Theodore E: 20 articles (01/2020 - 06/2002)
2.	Turpie, Alexander G G: 19 articles (07/2017 - 01/2002)
3.	Mehta, Shamir R: 17 articles (04/2015 - 03/2005)
4.	Yusuf, Salim: 17 articles (05/2014 - 03/2005)
5.	Bauer, Kenneth A: 17 articles (09/2008 - 01/2002)
6.	Akl, Elie A: 15 articles (12/2021 - 05/2008)
7.	Afzal, Rizwan: 15 articles (05/2014 - 03/2005)
8.	Bassand, Jean-Pierre: 15 articles (02/2010 - 03/2005)
9.	Chrolavicius, Susan: 14 articles (12/2010 - 12/2005)
10.	Barba, Maddalena: 13 articles (12/2021 - 05/2008)

Related Diseases

1.	Venous Thromboembolism 01/01/2004 - "The further randomized, double-blind PENTHIFRA-PLUS trial showed that extending fondaparinux prophylaxis from one to four weeks after hip fracture surgery was well tolerated and, compared to one-week fondaparinux, dramatically reduced delayed venous thromboembolism events from 35.0% to 1.4% (p<0.001). " 01/01/2008 - "In a well designed trial (ARTEMIS) in acute medical patients aged > or = 60 years, fondaparinux was significantly more effective than placebo in terms of reducing the incidence of venous thromboembolism (VTE) up to day 15. " 07/01/2004 - "In patients undergoing elective hip replacement surgery, fondaparinux significantly reduced the frequency of venous thromboembolism (VTE). " 01/01/2019 - "Conclusions Fondaparinux was associated with a superior efficacy in terms of reduction of venous thromboembolism in this meta-analysis. " 11/01/2012 - "Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study."
2.	Hemorrhage 04/30/2013 - "In one large, placebo-controlled RCT of about 3000 patients, subcutaneous fondaparinux was associated with a significant reduction in symptomatic VTE (RR 0.15; 95% CI 0.04 to 0.50), ST extension (RR 0.08; 95% CI 0.03 to 0.22), and ST recurrence (RR 0.21; 95% CI 0.08 to 0.54) with comparable rates of major bleeding (RR 0.99; 95% CI 0.06 to 15.86) relative to placebo. " 03/14/2012 - "In a placebo-controlled RCT of about 3000 patients, fondaparinux was associated with a significant reduction in symptomatic VTE (RR 0.15; 95% CI 0.04 to 0.50), extension (RR 0.08; 95% CI 0.03 to 0.22), and recurrence of ST (RR 0.21; 95% CI 0.08 to 0.54) with comparable rates of major bleeding (RR 0.99; 95% CI 0.06 to 15.86) relative to placebo. " 12/01/2003 - "In a subgroup analysis of several large randomized trials, fondaparinux, 2.5 mg, begun < 6 h postoperatively was associated with increased major bleeding, without improved efficacy. " 05/01/2011 - "Even in the context of low access site complication rate provided by TRA, fondaparinux was effective in reducing major bleeding." 09/01/2004 - "This superior efficacy led to an overall increase in major bleeding, which was however primarily due to more fondaparinux-treated patients with bleeding indexes of 2 or greater. "
3.	Thrombosis (Thrombus) 10/01/2017 - "Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients." 09/23/2010 - "Fondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treatment of patients with acute, symptomatic superficial-vein thrombosis of the legs and did not have serious side effects. " 03/21/2014 - "Given the development of new thromboses in 3 of 8 patients, concern exists about the efficacy of fondaparinux in this patient population. " 03/01/2012 - "In vitro studies support the effectiveness of fondaparinux in preventing thrombus formation on mechanical heart valves. " 04/01/2011 - "Fondaparinux for the treatment of superficial vein thrombosis in the legs: the CALISTO study."
4.	Acute Coronary Syndrome 04/01/2010 - "Fondaparinux sodium injection has been accepted for priority review by the United States Food and Drug Administration based on positive results from two pivotal, Phase III trials (OASIS 5 and 6) that evaluated its role in the treatment of a broad spectrum of patients with acute coronary syndromes (ACS). " 11/01/2005 - "Finally, a number of Phase II trials investigated the safety and efficacy of fondaparinux in patients with acute coronary syndromes, and a large Phase III program is ongoing in this setting. " 01/01/2006 - "Fondaparinux in acute coronary syndromes: improved efficacy and safety." 03/01/2022 - "Evaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population." 09/22/2010 - "Double-blind randomized parallel-group trial in 179 hospitals in 18 countries involving 2026 patients undergoing PCI within 72 hours, nested within a cohort of 3235 high-risk patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux enrolled from February 2009 to March 2010. "
5.	Venous Thrombosis (Deep-Vein Thrombosis) 07/01/2005 - "In conclusion, due to its superior efficacy and satisfactory safety, fondaparinux may substantially improve the prevention and treatment of venous thrombosis." 01/01/2002 - "This superior efficacy of fondaparinux was also demonstrated for proximal deep vein thrombosis with a reduction of 57.4%. " 01/01/2004 - "Fondaparinux recipients had a lower incidence of proximal deep vein thrombosis (DVT) in two studies. " 10/01/2020 - "During fondaparinux treatment, platelet count did not increase and a lower leg deep vein thrombosis occurred. " 05/01/2016 - "Anti-Xa assays are useful for monitoring the effects of selective anti-Xa drugs, such as fondaparinux, in the prophylaxis of deep vein thrombosis. "

Related Drugs and Biologics

1.	Enoxaparin (Lovenox)
2.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
3.	Heparin (Liquaemin)
4.	Anticoagulants
5.	Factor Xa Inhibitors
6.	bivalirudin (Angiomax)
7.	Antithrombins
8.	Vitamin K
9.	Rivaroxaban
10.	edoxaban

Related Therapies and Procedures

1.	Orthopedic Procedures
2.	Therapeutics
3.	Percutaneous Coronary Intervention
4.	Catheters
5.	Hip Replacement Arthroplasty (Total Hip Replacement)

HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Application Error

An application error has occurred and our support engineers have been notified.

Please use the browser "Back" button and try your operation again.

OR if the error persists and you require an email response
please contact us at "cs at curehunter.com":

Your request
The circumstances of the error
Your login id/nickname or email

Return to Top Page